Entrada Announces Selection of Second Clinical Trial Candidate

- Posted in Research

Entrada Therapeutics announced the selection of a second clinical candidate, ENTR-601-45, for the potential treatment of people living with Duchenne who are exon 45 skipping amenable.

Read more in the press release below.

Entrada-Therapeutics-Announces-Clinical-Candidate-ENTR-601-45-for-the-Potential-Treatment-of-People-Living-with-Duchenne-Muscular-Dystrophy-who-are-Exon-45-Skipping-AmenableDownload

Related Posts

Share This Page

Make an Impact

You can advance the care, treatment and cure for Duchenne muscular dystrophy. Contributions in any amount can truly make a difference and can be credited to a fundraiser or event from the list below.

Donate